Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading. In this study, we investigated the role of decorin in suppressing both primary breast carcinomas and pulmonary metastases. We show that decorin causes marked growth suppression both in vitro and in vivo using a metastatic breast cancer cell line and an orthotopic mammary carcinoma model. Treatment with decorin protein core reduced primary tumor growth by 70% and eliminated observed metastases. An adenoviral vector containing the decorin transgene caused primary tumor retardation of 70%, in addition to greatly reducing observed metastases. Moreover, we demonstrate that ErbB2 phosphorylation and total receptor protein levels are reduced in this model system upon de novo expression of decorin under the control of a doxycycline-inducible promoter. Primary tumor growth in vivo was reduced by up to 67% upon decorin induction, and pulmonary metastases were markedly hampered as well. These effects are likely occurring through decorin's long-term downregulation of the ErbB2 tyrosine kinase cascade. These results demonstrate a novel role for decorin in reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapeutics for metastatic breast cancer.
Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading. In this study, we investigated the role of decorin in suppressing both primary breast carcinomas and pulmonary metastases. We show that decorin causes marked growth suppression both in vitro and in vivo using a metastatic breast cancer cell line and an orthotopic mammary carcinoma model. Treatment with decorin protein core reduced primary tumor growth by 70% and eliminated observed metastases. An adenoviral vector containing the decorin transgene caused primary tumor retardation of 70%, in addition to greatly reducing observed metastases. Moreover, we demonstrate that ErbB2 phosphorylation and total receptor protein levels are reduced in this model system upon de novo expression of decorin under the control of a doxycycline-inducible promoter. Primary tumor growth in vivo was reduced by up to 67% upon decorin induction, and pulmonary metastases were markedly hampered as well. These effects are likely occurring through decorin's long-term downregulation of the ErbB2 tyrosine kinase cascade. These results demonstrate a novel role for decorin in reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapeutics for metastatic breast cancer. Keywords: decorin proteoglycan; adenovirus gene therapy; breast carcinoma; doxycycline inducible promoter The aggressive behavior of human breast cancer correlates with enhanced expression and activity of receptor tyrosine kinase, primarily of the epidermal growth factor or ErbB family (Carpenter, 2000) . Thus, therapeutic interventions focused on attenuating either the expression or the intrinsic activity of these receptors could represent useful anticancer treatments (Mendelsohn and Baselga, 2000) . Decorin, the prototype member of an expanding family of small leucine-rich proteoglycans, is involved in a number of cellular processes including matrix assembly, fibrillogenesis, and the control of cell proliferation (Iozzo, 1998 (Iozzo, , 1999 Reed and Iozzo, 2003) . Notably, decorin protein core is a biological ligand of the epidermal growth factor receptor (EGFR) (Iozzo et al., 1999b; Santra et al., 2002) , but unlike typical ligands, such as EGF and TGF-a, decorin/EGFR interaction leads to a transient activation of the receptor tyrosine kinase, followed by a protracted downregulation of its activity. Indeed, we have previously shown that decorin exerts an antioncogenic activity in various tumors, including squamous and adenocarcinomas, by suppressing both EGFR (Santra et al., 1997; Moscatello et al., 1998; Csorda´s et al., 2000) and ErbB2 activity. In either case, decorin causes a profound downregulation of these receptors both in vitro and in vivo, thereby providing a plausible explanation for its cytostatic effects. The cytostatic effects of decorin occur in a wide variety of tumor cell lines with a diverse histogenetic background (Santra et al., 1995 (Santra et al., , 1997 Nash et al., 1999) and can also affect murine tumor cells (Iozzo et al., 1999a) and normal cells such as endothelial cells (Scho¨nherr et al., 2001) and macrophages (Xaus et al., 2001) . Decorin can also indirectly retard tumor growth by blocking TGF-b (Yamaguchi et al., 1990) , by inhibiting tumor cell production of angiogenic factors such as VEGF (Grant et al., 2002) , or by interacting with antiangiogenic compounds such as thrombospondin-1 (de Lange Davies et al., 2001) . Our working hypothesis, validated by multiple studies from our group (Moscatello et al., 1998; Csorda´s et al., 2000; Santra et al., 2000) as well as by several independent studies (Nash et al., 1999; Tralha˜o et al., 2003) , is that decorin is a natural anticancer agent and enhancement of decorin gene expression should lead to a retardation of tumor growth. We have recently shown that transient transgene expression of a replication-deficient adenovirus (Ad)-containing decorin causes a profound growth inhibition of colon and squamous cell carcinoma xenografts . A key finding of our study was that decorin gene expression in the treated tumor xenografts correlated well with a decreased proliferative index and an attenuation of EGFR activation. Moreover, using the same construct it was subsequently found that directly intraneoplastic injection of Ad-decorin could affect not only the treated tumor xenograft but also a distant tumor on the contralateral side (Tralha˜o et al., 2003) .
In this study, we investigated whether decorin had any effects on the metastastic spreading of breast carcinoma cells in vivo. Our primary goal is to determine that decorin's mechanism of action, that is, downregulation of EGFR activity (Moscatello et al., 1998; Nash et al., 1999; Csorda´s et al., 2000; Santra et al., 2000; Reed et al., 2002; Tralha˜o et al., 2003) , has the far-reaching effect of reducing invasion of tumors and metastatic spread in vivo. This is a vital step to proving the relevance of decorin as a potent biological inhibitor of cancer. To this end, we utilized an established animal model in which spontaneously metastasizing rat MTLn3 breast carcinoma cells are injected in the mammary gland of virgin SCID animals to generate an orthotopic tumor xenograft. The MTLn3 express low EGFR number (B5 Â 10 4 /cell) and relatively high number (B5 Â 10 5 ) of ErbB2, similar to the human counterpart. These cells have been utilized in a number of studies (Wyckoff et al., 2000; Ahmed et al., 2002; Wang et al., 2002) and represent a valid model of orthotopic breast carcinoma xenograft. The MTLn3 grow very rapidly and within 2-3 weeks metastasize nearly exclusively to the lungs (Neri et al., 1982) . One week following tumor implantation, we injected intratumorally highly purified decorin protein core (60 mg/animal) (Figure 1a) , and repeated the same treatment for another two times in the following 2 weeks. The total dosage was 7.2 mg/kg of body weight. The results showed a marked suppression of primary tumor growth (Po0.001) 4 weeks after implantation ( Figure 1b) . In spite of the fact that the decorin-treated tumors had a morphology similar to the untreated (not shown), and that they reached a sizable tumor of B500 mg (Figure 1b) , we found neither gross nor microscopic lung metastases ( Figure 1c ). All the lungs were completely analysed by serial sectioning and we found only a few cell aggregates, possibly incipient metastases, in the decorin group. In contrast, the animals treated with vehicle alone clearly showed a significant number of metastases, which we subdivided into three categories based on their average size ( Figure 1d ).
Next, we determined whether adenovirus-decorin (Ad-Dcn) was capable of efficiently transducing the rat MTLn3 tumor cells. The results showed a significant expression of the virally transduced decorin gene (a) SDS-PAGE of decorin protein core. Recombinant human decorin was expressed as a polyhistidine fusion protein in 293-EBNA cells using a Celligen Plus bioreactor (New Brunswick Scientific, NJ, USA) as described previously (Goldoni et al., 2004) . Proteoglycan and protein core were purified over a nickel-chelating column followed by elution with a gradient of 0-250 mM imidazole in 20 mM Tris-HCl, 500 mM NaCl, 0.2% CHAPS, pH 8.0. Protein core was subsequently separated from proteoglycan by anion-exchange chromatography on Q-Sepharose. Differential glycosylation of decorin protein core resulted in the expected doublet migrating with an apparent molecular mass of 50-55 kDa (Ramamurthy et al., 1996) . In total, 2 mg of purified decorin protein core was visualized following electrophoresis on a 10% polyacrylamide and staining with Coomassie brilliant blue. (b) Decorin protein core inhibits the growth of an orthotopic breast carcinoma. MTLn3 cells ( B10 6 ) were injected into the breast of female SCID mice (n ¼ 4). Decorin protein core (60 mg protein/injection) or PBS (control) was injected directly into developing tumors. Three treatments were administered as indicated by vertical arrows. Graph indicates mean tumor volume as determined by the formula v ¼ a Â b 2 /2, where a is the longest axis and b is perpendicular to a. Values represent the mean7s.e.m. (c) Decorin protein core eliminates pulmonary metastases in vivo. Upon concluding the in vivo protein treatment, lungs of all animals were dissected, fixed, sectioned, and examined histologically for tumor metastases. Size I indicates metastases of under 100 mm, size II from 101-200 mm, and size III >200 mm. Graph indicates total metastases found in all animals. (d) Photomicrographs of three classes of pulmonary metastases in vivo. Lungs were paraffin embedded, sectioned at multiple levels, and stained with hematoxylin and eosin. Observed metastases stained differentially (blue nodules) compared to surrounding lung tissue. Scale bars ¼ 300 mm Suppression of breast cancer metastases by decorin CC Reed et al transcript, a single B1.9 kb band detected after only 2 h of exposure (Figure 2a ), whose levels increased in a dose-dependent manner. In agreement with previous results which have clearly demonstrated that decorin is a product of mesenchymal cells rather than epithelial cells (Adany et al., 1990; Santra et al., 1997; Nash et al., 2002; Koninger et al., 2004) , no decorin message was detected in the MTLn3 breast carcinoma cells treated with either buffer or empty vector, even after a long exposure (Figure 2a) . The de novo expression of decorin correlated with a reduction of in vitro tumor cell growth (Po0.01) (Figure 2b ). The high efficiency of transduction and the relatively high levels of transgene expression mediated by the adenoviral vector in cultured cells prompted us to investigate the antioncogenic properties of decorin in vivo by direct intraneoplastic injection of the Ad-Dcn. The results showed a marked inhibition of tumor growth (Figure 2c ). At the end of the experiments, the decrease in tumor volume for the Ad-Dcntreated breast carcinoma xenografts reached B70% (Po0.001) (Figure 2c ). In a previous publication , we demonstrated by immunohistochemistry lowered levels of activated EGFR, along with a reduced proliferative index, in tumors following treatment with adenoviral decorin. These results were both confirmed and extended in an independent publication using the identical decorin viral vector (Tralha˜o et al., 2003) . We have additionally observed decreased levels of activated EGFR following in vivo tumorigenesis experiments with cells constitutively expressing decorin (Csorda´s et al., 2000) . Thus, both topical delivery of recombinant human decorin protein core and transduction of tumor xenografts with Ad-Dcn have substantial cytostatic effects in an animal model of aggressive breast cancer.
There was also, in addition to primary tumor inhibition, a significant inhibition of metastatic spreading to the lungs (Figure 2d ), albeit not as striking as with the recombinant decorin protein core. Immunohistochemistry to observe decorin in pulmonary metastases of adenoviral-treated animals was negative, due most likely to the transient and local nature of viral treatment (data not shown). We presume that the difference in observed metastases is due to differences in decorin levels, since the Ad-Dcn would produce decorin levels in the low microgram range and would only be transiently expressed, while the dosages with the recombinant decorin core were likely much higher and were presented to the nascent tumors in a bolus.
Conditional regulation of gene expression in the course of in vivo tumor progression provides important insights into the role of gene products during different phases of tumor development. To determine whether the endogenous production of decorin would also produce a retardation of growth and a reduced metastatic burden, we generated stably transfected clones of the MTLn3 cells expressing decorin controlled by a Dox-inducible promoter (Gossen and Bujard, 1992) . We utilized the Rev Tet-Ont (BD Bioscience) system due to its high level of inducible expression, quantitative regulation of gene expression, and minimal pleiotropic and nonspecific effects. We generated several stable clones that were highly inducible by exposure to Dox for 48 h following transfection with the pRevTRE-luciferase construct (Figure 3a) . Representative immunoblotting of media from clone 13 showed a significant induction of decorin proteoglycan by doxycycline treatment with minimal promoter leakage (Figure 3b) . Notably, the overall amount of ErbB2 receptor that could be immunoprecipitated with a specific monoclonal antibody was significantly reduced (Figure 3c ). Quantification of several immunoprecipitation experiments revealed a mean 60% reduction in ErbB2 levels (Figure 3d) . However, the degree of phosphorylation of ErbB-2 was reduced by over 80% (Figure 3d) . These results are similar to those obtained with stable expression of decorin in human mammary carcinoma cells which also overexpress ErbB2 . The changes in ErbB2 activity correlated with a significant in vitro (Figure 3e ). Induced cells also demonstrated a greatly reduced ability to proliferate in a hydrated three-dimensional collagen matrix (Figure 3f) , with over 75% fewer colonies formed after 5 days in culture (Figure 3g ). Reduced ability to grow in a three-dimensional lattice demonstrates in vitro that cells expressing decorin exhibit reduced aggressiveness and invasive potential, and correlates well with the .7, and 13a.10 were scanned and densitometry was performed using NIH Image program. Bands from uninduced cells were set to an arbitrary value of one for quantification and the means of scanning densitometry results from the three blots were plotted. Error bars indicate s.e.m. (e) Cell growth assay of clone 13a.5 in the presence or absence of Dox (5 mg/ml) as indicated. About 10 4 cells were plated in triplicate on day 0 in the presence or absence of Dox and grown for 6 days in complete medium. Cells were counted and results plotted. Growth inhibition of 67% was observed in induced cells. Similar results were obtained with other clones (not shown). (f) Hydrated collagen lattice growth assay. Collagen gels (2.48 mg/ml) (BD Biosciences) were prepared with aMEM and mixed with 5 Â 10 4 cells of clone 13a.5. Wells were prepared in triplicate. Cells were induced with Dox (5 mg/ml) for 5 days, after which photographs were taken and colonies counted. (g) Quantification of collagen gel lattice assay. Wells were counted in triplicate. Graph displays mean7s.e.m.
reduced ErbB2 activity and significant growth inhibition previously observed.
In vivo, the tumor growth inhibition was performed in two independent experiments, and demonstrated nearly identical results of B70% inhibition of primary tumors (Figure 4a and c) . In addition, there were 57% fewer microscopic metastases observed in the lungs in one experiment and no observable metastases in the second (Figure 4b and d) . Immunohistochemical staining using an antibody specific for the N-terminal portion of human decorin revealed that decorin was localized either at the periphery of the tumors (Figure 4g ) or in the tumor stroma (Figure 4h-j, arrows) . Uninduced tumors showed no detectable levels of decorin (not shown). Specificity of the antibody was assessed by staining of human dermis ( Figure 4f) ; no positive reaction was observed when the primary antibody was omitted (Figure 4e ). The pattern of decorin expression and cell morphology in tumors is similar to previously observed decorin in orthotopic tumor xenografts following adenoviral decorin treatment . It is possible that cells in the tumor periphery, with greater access to blood supply and, by extension, doxycycline, secrete the induced gene more efficiently. Alternatively, decorin could be concentrating in these regions by a not yet understood mechanism. The overall amounts of decorin detected in induced tumors are low, underscoring the potency of decorin in growth inhibition and Figure 4 Induction of decorin reduces growth and invasive potential in vitro and in vivo. (a, c) Tumor growth in vivo is inhibited by induction of decorin. Two independent experiments were performed with clone 13a.5 cells (B10 6 ) engineered to conditionally express decorin via a Dox-sensitive promoter. Cells were injected subcutaneously into the breast of female SCID mice (n ¼ 5 for each group). Induced cells were exposed to Dox (5 mg/ml) and animals were likewise given Dox (500 mg/ml) and sucrose (50 mg/ml) in drinking water, or sucrose alone, 24 h prior to injection. Dox water was replaced every 2 days during the course of the experiment. Note that, in the decorin induction experiments, the overall amount of tumor metastases was lower than the previous in vivo trials, possibly due to the slight leakage of the Tet promoter. It is known that low levels of decorin in invasive breast carcinomas have been associated with larger tumor size, shortened time to progression, and poor outcome (Troup et al., 2003) . These results show that decorin causes a significant growth suppression of rat breast carcinoma cells and could inhibit metastases to the lungs as a result of the decreased tumor size. Alternatively, decorin itself could be directly involved in a mechanism regulating the behavior of metastatic cells by lowering their tendency to spread. Overexpression of EGFR and ErbB2 has been shown to stimulate cell migration, which is an important step in metastasis (Verbeek et al., 1998) . Breaking the signaling cascade of the EGFR pathway should, therefore, correlate with reduced metastatic spread and better overall prognosis in vivo. Decorin's proven downregulation of EGFR/ErbB2, demonstrated both in the present study and in others Reed et al., 2002) , point to a role for decorin in slowing the spread of metastases through either reduction in primary tumor growth or possibly also through direct or indirect signaling mechanisms at the sites of metastasis. These results could have important clinical implications as metastases to the lungs are lethal in patients with breast cancer. Collectively, these results provide strong evidence for the in vivo antiproliferative effects of decorin and suggest that, at least in part, decorin inhibits the proliferation of tumor cells by interfering with ErbB2 activity.
Our results further underscore the possibility of decorin as a viable therapeutic, either alone or in combination, for several types of cancers. Previous work with decorin delivered by an adenoviral vector showed decorin's efficacy against several in vivo tumor models Tralha˜o et al., 2003) , and the results here not only reinforce these results, but extend them into the combating of a serious clinical problem -that of secondary tumor metastases. We have used several tools, including viral vector-mediated gene delivery, to induce decorin's effects. Gene transfer methods to deliver decorin in a therapeutic setting are, we believe, a distinct prospect in the future, especially in light of decorin's proven synergistic effects with other therapeutic modalities in inhibiting cancer cells (Nash et al., 1999) . Decorin gene delivery offers distinct advantages, including the ability to affect many nearby cell-surface receptors from a single transduction event, since decorin is secreted into the surrounding environment and acts extracellularly (Iozzo, 1999) . This is of great value in systems where effective transduction is variable or unpredictable. Decorin is also a natural product and therefore should not be immunogenic by itself. Through its interaction with ErbB tyrosine kinase family members and the subsequent functional downregulation of such, decorin could lead to remarkable growth delay or arrest in a variety of solid tumors. In addition to this, we have presented strong evidence that not only does decorin affect primary tumors but also can potentially slow or halt distant metastases. While a great deal of work needs to be carried out to adequately explore this, our results indicate that limiting distant metastatic growth with nontoxic, biological compounds is an achievable goal.
Abbreviations Ad-Dcn, adenovirus-decorin; EGFR, epidermal growth factor receptor; PFU, plaque-forming units; HRP, horseradish peroxidase.
